For research use only
| Cat No. | ABC-TC0214 |
| Product Type | Human Lung Cancer Cell Lines |
| Species | Human |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Pleural Fluid |
| Disease | Lung Small Cell Cancer |
| Product Code | DMS-273; DMS273 |
DMS 273 cell line is a human small-cell lung carcinoma model for cancer biology, drug screening, and molecular pathway research in oncology.
DMS 273 is a human small cell lung carcinoma (SCLC) cell line derived in 1978 from the pleural fluid of a 50-year-old Caucasian female patient who had relapsed following chemotherapy and radiotherapy. Originating from small cell carcinoma of the lung, these cells exhibit an epithelial morphology, grow in adherent clusters, and retain features of small cell carcinoma, and are commonly cultured in media formulations such as Waymouth’s MB 752/1 medium. DMS 273 is characterized by a complex hypotriploid karyotype and mutations commonly associated with SCLC, including loss-of-function TP53 (G245C) and RB1 mutations. DMS 273 cells demonstrate high tumorigenic potential in immunocompromised mouse xenografts and are responsive to several chemotherapeutic agents, making them a reliable preclinical model for studying drug resistance and metastasis in aggressive lung cancers and are frequently referenced in datasets and screening studies under the broader DMS cancer classification.
| Product Code | DMS-273; DMS273 |
| Species | Human |
| Cat.No | ABC-TC0214 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Growth Mode | Adherent |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Pleural Fluid |
| Disease | Lung Small Cell Cancer |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Human Lung Cancer Cell Lines |
DMS-273 is a valuable cell line for studying small-cell lung cancer (SCLC), an aggressive cancer known for its high metastatic potential. Transplanting DMS-273 into the lungs of nude mice creates a metastasis model and facilitates the testing of drugs or inhibitors. For instance, DMS-273 exhibits amplification of the SETDB1 gene, resulting in the overexpression of SETDB1 protein, enhancing cell invasion in lung carcinoma. This finding provides insights into the potential application of SETDB1 inhibitors as new therapies. Similarly, in DMS-273, inhibitors or siRNA targeting signaling pathways associated with cancer progression and invasion can be tested to impede the progression of SCLC.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $200 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
